[go: up one dir, main page]

WO2013093465A3 - Formulations - Google Patents

Formulations Download PDF

Info

Publication number
WO2013093465A3
WO2013093465A3 PCT/GB2012/053195 GB2012053195W WO2013093465A3 WO 2013093465 A3 WO2013093465 A3 WO 2013093465A3 GB 2012053195 W GB2012053195 W GB 2012053195W WO 2013093465 A3 WO2013093465 A3 WO 2013093465A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
relates
binding moiety
polypeptide binding
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2012/053195
Other languages
French (fr)
Other versions
WO2013093465A2 (en
Inventor
Jonas Heilskov Graversen
Gabriele Anton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CYTOGUIDE APS
SMITH STEPHEN E
Original Assignee
CYTOGUIDE APS
SMITH STEPHEN E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CYTOGUIDE APS, SMITH STEPHEN E filed Critical CYTOGUIDE APS
Publication of WO2013093465A2 publication Critical patent/WO2013093465A2/en
Publication of WO2013093465A3 publication Critical patent/WO2013093465A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to storage-stable compositions comprising a polypeptide binding moiety and a therapeutic agent, wherein the polypeptide binding moiety is conjugated to the therapeutic agent by an ester bond and wherein the composition has an acidic pH. The invention also relates to methods, uses and kits comprising such compositions.
PCT/GB2012/053195 2011-12-23 2012-12-19 Novel formulations Ceased WO2013093465A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1122325.2A GB201122325D0 (en) 2011-12-23 2011-12-23 Novel formulations
GB1122325.2 2011-12-23

Publications (2)

Publication Number Publication Date
WO2013093465A2 WO2013093465A2 (en) 2013-06-27
WO2013093465A3 true WO2013093465A3 (en) 2013-12-19

Family

ID=45573052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/053195 Ceased WO2013093465A2 (en) 2011-12-23 2012-12-19 Novel formulations

Country Status (2)

Country Link
GB (1) GB201122325D0 (en)
WO (1) WO2013093465A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359194A4 (en) * 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-MEDICINAL CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
CN105467024A (en) * 2015-11-17 2016-04-06 宁夏泰瑞制药股份有限公司 Detection method of Tildipirosin content
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20200007905A (en) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 Cyclodextrin protein drug conjugate
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
EA202091672A1 (en) 2018-01-08 2021-02-01 Регенерон Фармасьютикалз, Инк. STEROIDS AND THEIR ANTIBODY-CONJUGATES
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US20210077632A1 (en) * 2019-08-15 2021-03-18 Silverback Therapeutics, Inc. Formulations of Benzazepine Conjugates and Uses Thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN116209678A (en) 2020-07-01 2023-06-02 安尔士制药公司 anti-ASGR 1 antibody conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011039511A2 (en) * 2009-09-29 2011-04-07 Cytoguide A/S Agents, uses and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039578B1 (en) 1980-05-02 1985-04-10 Edward P. Davis Leg aid device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
NO314537B1 (en) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Receptor binding conjugates
PT1328297E (en) 2000-10-16 2010-01-04 Cytoguide Aps The function of a haptoglobin-haemoglobin receptor and the uses thereof
EP1318195A1 (en) 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
DE102004034008A1 (en) 2004-07-14 2006-02-09 Rösner Research GmbH & Co.KG Process for the preparation of albumin-corticoid conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011039511A2 (en) * 2009-09-29 2011-04-07 Cytoguide A/S Agents, uses and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUILLEMARD V ET AL: "Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 61, no. 2, 15 January 2001 (2001-01-15), pages 694 - 699, XP002203756, ISSN: 0008-5472 *
YASUSHI ARANO ET AL: "A NOVEL BIFUNCTIONAL METABOLIZABLE LINKER FOR THE CONJUGATION OF ANTIBODIES WITH RADIONUCLIDES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 2, no. 2, 1 March 1991 (1991-03-01), pages 71 - 76, XP000201525, ISSN: 1043-1802, DOI: 10.1021/BC00008A001 *

Also Published As

Publication number Publication date
GB201122325D0 (en) 2012-02-01
WO2013093465A2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
WO2013093465A3 (en) Formulations
WO2012042371A3 (en) Pharmaceutical composition
WO2010141694A3 (en) Borinic compositions
WO2012032523A3 (en) Compositions comprising acidic extracts of mastic gum
WO2012170889A8 (en) Cleavable lipids
WO2012077120A3 (en) Natural formulations
WO2011059866A3 (en) Composition and methods for improving skin appearance
WO2008157635A3 (en) Synthetic bile acid composition, method, and preparation
WO2012033814A3 (en) Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
WO2013103301A3 (en) Method for preparing cell targeting conjugates, and the complexes obtained
WO2012112767A3 (en) Collagen-targeted nanoparticles
WO2012021133A9 (en) Synthetic bile acid compositions and methods
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2011015882A3 (en) Anhydrate of triotropium bromide
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2011091221A3 (en) Manganese tetrathiotungstate material
WO2009100272A3 (en) Effervescent compositions
MX2009008249A (en) Pharmaceutical composition comprising a campothecin derivative.
WO2012038469A3 (en) Cosmetic composition
AU2009298305A8 (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (GnRH) as immunogen
UA114082C2 (en) METHOD OF PREPARATION OF WATER-SOLUBLE SELENGLYPROTEINS AND THE COMPOSITION CONTAINING THEM
WO2011102999A3 (en) Spink1 targeted therapy
WO2011029516A3 (en) Cosmetic composition with an antimicrobial effect
WO2009084020A3 (en) Topical composition comprising halobetasol and salicylic acid
WO2012116992A3 (en) Oral use of a composition comprising steviol or isosteviol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12816321

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12816321

Country of ref document: EP

Kind code of ref document: A2